Nadav Cohen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nadav Cohen has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Ofer Lavie
Department of Obstetrics and Gynecology Lady Davis Carmel Medical Center Haifa Israel
10 shared publicationsAriel Zilberlicht
Department of Obstetrics and Gynecology, Carmel Lady Davis Medical Center, Haifa, Israel; The Rappaport Faculty of Medicine, Technion - Haifa, Israel
6 shared publicationsHagit Itzhak Kedem
The Rappaport Faculty of Medicine, Technion - Haifa, Israel
3 shared publicationsMoran Paz
Department of Obstetrics and Gynecology, Lady Davis Carmel Medical Center, Haifa, Israel
3 shared publications- Wisam Assaf
Department of Obstetrics and Gynecology Lady Davis Carmel Medical Center Haifa Israel
3 shared publications Yuval Kaufman
Department of Obstetrics and Gynecology, Lady Davis Carmel Medical Center, Haifa, Israel
3 shared publications
Latest Publications
- Open Access
- 26 July 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (5) , 1218-1227
Mild Thrombocytopenia and the Risk of Post‐Partum Hemorrhage
Background: Mild thrombocytopenia is common in pregnancy and considered benign. However, its association with postpartum hemorrhage (PPH) remains unclear, with emerging evidence suggesting a potential increase in bleeding risk. Objective: To evaluate whether mild thrombocytopenia is independently associated with PPH risk. Search Strategy: We performed an electronic search using MEDLINE(R) with the OvidSP interface and PUBMED, Embase, Web of Science, Cochrane Library, and Clinicaltrials.gov up to April 8, 2025. Selection Criteria: We included observational studies evaluating the association between mild thrombocytopenia and PPH. Main Results: Eight retrospective studies encompassing 79 126 women were included, of whom 9496 had mild thrombocytopenia. Mild thrombocytopenia was associated with increased risk of PPH (OR 1.68; 95% CI 1.25–2.26; I 2 = 89%). Women with mild thrombocytopenia had higher risks of blood transfusion (OR 1.47; 95% CI 1.11–1.97) and hemoglobin decline ≥ 3 g/dL (OR 1.56; 95% CI 1.03–2.36). Conclusion: Mild thrombocytopenia was associated with an increased risk of PPH and related hemorrhagic outcomes in the available retrospective studies. Although these findings do not establish a causal relationship, they suggest that mild thrombocytopenia may represent a clinically relevant risk marker that could be considered during peripartum risk assessment. Prospective studies using standardized definitions of PPH are needed to confirm these findings. Study protocol can be assessed at PROSPERO International prospective register of systematic reviews ( http://www.crd.york.ac.uk/PROSPERO , registration number CRD42025642731).
- 26 July 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (5) , 1218-1227
Open AccessMild Thrombocytopenia and the Risk of Post‐Partum Hemorrhage
Background: Mild thrombocytopenia is common in pregnancy and considered benign. However, its association with postpartum hemorrhage (PPH) remains unclear, with emerging evidence suggesting a potential increase in bleeding risk. Objective: To evaluate whether mild thrombocytopenia is independently associated with PPH risk. Search Strategy: We performed an electronic search using MEDLINE(R) with the OvidSP interface and PUBMED, Embase, Web of Science, Cochrane Library, and Clinicaltrials.gov up to April 8, 2025. Selection Criteria: We included observational studies evaluating the association between mild thrombocytopenia and PPH. Main Results: Eight retrospective studies encompassing 79 126 women were included, of whom 9496 had mild thrombocytopenia. Mild thrombocytopenia was associated with increased risk of PPH (OR 1.68; 95% CI 1.25–2.26; I 2 = 89%). Women with mild thrombocytopenia had higher risks of blood transfusion (OR 1.47; 95% CI 1.11–1.97) and hemoglobin decline ≥ 3 g/dL (OR 1.56; 95% CI 1.03–2.36). Conclusion: Mild thrombocytopenia was associated with an increased risk of PPH and related hemorrhagic outcomes in the available retrospective studies. Although these findings do not establish a causal relationship, they suggest that mild thrombocytopenia may represent a clinically relevant risk marker that could be considered during peripartum risk assessment. Prospective studies using standardized definitions of PPH are needed to confirm these findings. Study protocol can be assessed at PROSPERO International prospective register of systematic reviews ( http://www.crd.york.ac.uk/PROSPERO , registration number CRD42025642731).
- 19 May 2025
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 311, 114067
Risk factors for procedural interventions for retained products, after failed treatment with misoprostol or mifepristone and misoprostol for first trimester pregnancy loss – A retrospective cohort study
- 19 May 2025
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 311, 114067
Risk factors for procedural interventions for retained products, after failed treatment with misoprostol or mifepristone and misoprostol for first trimester pregnancy loss – A retrospective cohort study
- 6 May 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (6) , 1773-1779
Oral GnRH antagonists for ovulation suppression during ovarian stimulation protocols: systemic review and meta-analysis
Purpose The impact of oral GnRH antagonists on IVF treatment outcomes remains unclear. The aim of the study is to investigate the impact of GnRH antagonist over the outcomes of IVF. Methods We performed an electronic search using MEDLINE® with the OvidSP interface PUBMED, Embase, Web of Science, and Cochrane Library up to December 16, 2024. We included experimental and non-experimental studies, assessing the role of oral GnRH during controlled ovarian stimulation protocols. Our main outcomes were cycle cancelation rate and mean number of mature oocytes retrieved at oocyte pickup (OPU) day. Results We included four studies comprising 813 patients, of whom 452 women received oral GnRH antagonists and 294 received injectable subcutaneous GnRH antagonists. No statistical differences were noted in the meta-analysis between each outcome measured (cycle cancelation, mean overall and mature oocytes, fertilization rate, and blastulation rate). Using the GRADE criteria, the overall quality of the existing evidence was determined as moderate. Conclusions This is the first systemic review and meta-analysis to examine the usage of oral GnRH antagonists for ovulation suppression during IVF treatments. Our findings suggest the use of oral GnRH antagonists may be beneficial in infertility treatments; however, caution should be taken, as robust establishment of their effectivity and safety in clinical practice is still pending. Trial registration Registration Number: PROSPERO study ID: CRD42024599730
- 6 May 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (6) , 1773-1779
Oral GnRH antagonists for ovulation suppression during ovarian stimulation protocols: systemic review and meta-analysis
Purpose The impact of oral GnRH antagonists on IVF treatment outcomes remains unclear. The aim of the study is to investigate the impact of GnRH antagonist over the outcomes of IVF. Methods We performed an electronic search using MEDLINE® with the OvidSP interface PUBMED, Embase, Web of Science, and Cochrane Library up to December 16, 2024. We included experimental and non-experimental studies, assessing the role of oral GnRH during controlled ovarian stimulation protocols. Our main outcomes were cycle cancelation rate and mean number of mature oocytes retrieved at oocyte pickup (OPU) day. Results We included four studies comprising 813 patients, of whom 452 women received oral GnRH antagonists and 294 received injectable subcutaneous GnRH antagonists. No statistical differences were noted in the meta-analysis between each outcome measured (cycle cancelation, mean overall and mature oocytes, fertilization rate, and blastulation rate). Using the GRADE criteria, the overall quality of the existing evidence was determined as moderate. Conclusions This is the first systemic review and meta-analysis to examine the usage of oral GnRH antagonists for ovulation suppression during IVF treatments. Our findings suggest the use of oral GnRH antagonists may be beneficial in infertility treatments; however, caution should be taken, as robust establishment of their effectivity and safety in clinical practice is still pending. Trial registration Registration Number: PROSPERO study ID: CRD42024599730
- 28 November 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (6) , 3029-3035
Evaluation of postpartum dysglycemia by serum glycosylated hemoglobin in patients with gestational diabetes mellitus: a national data analysis
Purpose To assess the postpartum sensitivity and accuracy of serum HbA1c levels, compared to the gold standard of 75-g Oral Glucose Tolerance Test (OGTT), for diagnosis of dysglycemia in patients with a history of gestational diabetes mellitus (GDM). Methods A nationwide retrospective analysis of individuals with a history of GDM and with records of both postpartum 2 h-OGTT and serum HbA1c measured anytime between delivery until 12 months post-delivery. Results were stratified into 3 different intervals: 0–3 months, 3–12 months, and > 12 months after delivery, according to the timing of both OGTT and HbA1c performance. Results Between January 1st, 2015, until December 31st, 2021, a total of 55,119 individuals were screened, and 9,118 were diagnosed with GDM. Overall, 677 of the 9,118 individuals with GDM had laboratory results of both serum HbA1c levels and 2 h 75-gm-OGTT values after delivery. The overall Pearson correlation coefficient between HbA1c and 2 h-OGTT was 0.21 (P < 0.0001). However, when the OGTT results were stratified into 2 h-glucose values ≥ 200 mg/dL, a ROC curve yielded an Area Under the Curve (AUC) of 91.4% [95% CI: 83.9%-98.9%], with HbA1c levels of 5.7% yielding 80.0% sensitivity and 80.8% specificity (95% CI: 44.39–97.48%). Conclusions In patients with a recent diagnosis of GDM, serum HbA1c may be used as an auxiliary tool for postpartum diagnosis of dysglycemia.
- 28 November 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (6) , 3029-3035
Evaluation of postpartum dysglycemia by serum glycosylated hemoglobin in patients with gestational diabetes mellitus: a national data analysis
Purpose To assess the postpartum sensitivity and accuracy of serum HbA1c levels, compared to the gold standard of 75-g Oral Glucose Tolerance Test (OGTT), for diagnosis of dysglycemia in patients with a history of gestational diabetes mellitus (GDM). Methods A nationwide retrospective analysis of individuals with a history of GDM and with records of both postpartum 2 h-OGTT and serum HbA1c measured anytime between delivery until 12 months post-delivery. Results were stratified into 3 different intervals: 0–3 months, 3–12 months, and > 12 months after delivery, according to the timing of both OGTT and HbA1c performance. Results Between January 1st, 2015, until December 31st, 2021, a total of 55,119 individuals were screened, and 9,118 were diagnosed with GDM. Overall, 677 of the 9,118 individuals with GDM had laboratory results of both serum HbA1c levels and 2 h 75-gm-OGTT values after delivery. The overall Pearson correlation coefficient between HbA1c and 2 h-OGTT was 0.21 (P < 0.0001). However, when the OGTT results were stratified into 2 h-glucose values ≥ 200 mg/dL, a ROC curve yielded an Area Under the Curve (AUC) of 91.4% [95% CI: 83.9%-98.9%], with HbA1c levels of 5.7% yielding 80.0% sensitivity and 80.8% specificity (95% CI: 44.39–97.48%). Conclusions In patients with a recent diagnosis of GDM, serum HbA1c may be used as an auxiliary tool for postpartum diagnosis of dysglycemia.
- Open Access
- 13 September 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 168 (2) , 774-782
Evaluation of sonographic and clinical measures in early versus late third trimester for birth weight prediction
Objective: To evaluate the optimal timing for fetal weight estimation during the third trimester. Methods: This retrospective cohort study involved fetal weight estimations from both early (28 +0 –36 +6 weeks) and late (37 +0 weeks and beyond) third trimester. These estimations were converted to predicted birth weights using the gestation‐adjusted projection formula. Birth weight predictions were compared with actual birth weights, to identify the most effective timing for weight prediction. Results: The study included 3549 cases, revealing mean percentage errors (MPE) of −3.69% for early sonographic assessments, −2.5% for late sonographic assessments, and −1.9% for late clinical assessments. A significant difference was found between early and late sonographic estimations ( P < 0.001), whereas late sonographic and clinical assessments did not differ significantly ( P = 0.771). Weight predictions for fetuses below the 10th and above the 90th centiles were less accurate than for those within the 10th–90th centiles ( P < 0.001). In women with obesity, late clinical estimations were less precise (MPE of −5.85) compared with non‐obese women (MPE of −1.66, P < 0.001). For women with diabetes, early sonographic estimations were more accurate (MPE of −1.31) compared with non‐diabetic patients (MPE of −3.94, P < 0.001) though this difference did not persist later in pregnancy. Conclusion: Sonographic and clinical weight predictions in the late third trimester were more accurate than earlier third‐trimester sonographic assessments, hence continuous follow up and assessments closer to term are important. In women with diabetes, no adjustments in weight prediction methods are necessary. Accurately predicting birth weights for abnormally small or large fetuses remains challenging, indicating the need for improved screening and diagnostic strategies.
- 13 September 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 168 (2) , 774-782
Open AccessEvaluation of sonographic and clinical measures in early versus late third trimester for birth weight prediction
Objective: To evaluate the optimal timing for fetal weight estimation during the third trimester. Methods: This retrospective cohort study involved fetal weight estimations from both early (28 +0 –36 +6 weeks) and late (37 +0 weeks and beyond) third trimester. These estimations were converted to predicted birth weights using the gestation‐adjusted projection formula. Birth weight predictions were compared with actual birth weights, to identify the most effective timing for weight prediction. Results: The study included 3549 cases, revealing mean percentage errors (MPE) of −3.69% for early sonographic assessments, −2.5% for late sonographic assessments, and −1.9% for late clinical assessments. A significant difference was found between early and late sonographic estimations ( P < 0.001), whereas late sonographic and clinical assessments did not differ significantly ( P = 0.771). Weight predictions for fetuses below the 10th and above the 90th centiles were less accurate than for those within the 10th–90th centiles ( P < 0.001). In women with obesity, late clinical estimations were less precise (MPE of −5.85) compared with non‐obese women (MPE of −1.66, P < 0.001). For women with diabetes, early sonographic estimations were more accurate (MPE of −1.31) compared with non‐diabetic patients (MPE of −3.94, P < 0.001) though this difference did not persist later in pregnancy. Conclusion: Sonographic and clinical weight predictions in the late third trimester were more accurate than earlier third‐trimester sonographic assessments, hence continuous follow up and assessments closer to term are important. In women with diabetes, no adjustments in weight prediction methods are necessary. Accurately predicting birth weights for abnormally small or large fetuses remains challenging, indicating the need for improved screening and diagnostic strategies.
- 1 July 2024
- Vol. 26 (7-8) , 415-420
Neuraxial Morphine Anesthesia Given During Cesarean Delivery and Risk of Urinary Retention: A Retrospective Study
Background: Cesarean deliveries (CD) are commonly performed using neuraxial anesthesia. The use of neuraxial morphine has proven beneficial in terms of postoperative pain management; however, its effect on postoperative urine retention remains unclear. Objectives: To determine whether morphine injection into the neuraxis during CD influences postoperative urinary retention rate. Methods: We conducted a retrospective case-control observational study of patients undergoing CD. We compared patients using morphine injected into the intrathecal or epidural spaces (November 2020 to October 2021) to a historical cohort of patients undergoing CD without morphine (November 2019 to October 2020). The primary outcome was the rate of postoperative overt urinary retention necessitating bladder catheterization. Results: The study group comprised 283 patients, and 313 patients in the control group were eligible for analysis. No dif-- ferences were found with respect to the baseline demographic and indication for CD. The number of postpartum urinary bladder catheterizations due to urine retention was higher in the study group (5% vs. 1%, P-value = 0.003). No cases of 30- day readmission were recorded. Moreover, patients treated with neuraxial morphine required fewer repeat doses of postoperative anesthesia (oral analgesia 7.4 vs. 10.1, intravenous analgesia 0.29 vs. 0.31, oral opioids 0.06 vs. 3.70, intravenous opioids 0.01 vs. 0.45, P-value < 0.001 for all) Conclusions: While neuraxial morphine used during CD appears to be safe and effective, the risk of postoperative urinary retention seems to be increased due to its use. Cases of overt urinary retention treated by bladder catheterization does not lead to short-term complications.
- 1 July 2024
- Vol. 26 (7-8) , 415-420
Neuraxial Morphine Anesthesia Given During Cesarean Delivery and Risk of Urinary Retention: A Retrospective Study
Background: Cesarean deliveries (CD) are commonly performed using neuraxial anesthesia. The use of neuraxial morphine has proven beneficial in terms of postoperative pain management; however, its effect on postoperative urine retention remains unclear. Objectives: To determine whether morphine injection into the neuraxis during CD influences postoperative urinary retention rate. Methods: We conducted a retrospective case-control observational study of patients undergoing CD. We compared patients using morphine injected into the intrathecal or epidural spaces (November 2020 to October 2021) to a historical cohort of patients undergoing CD without morphine (November 2019 to October 2020). The primary outcome was the rate of postoperative overt urinary retention necessitating bladder catheterization. Results: The study group comprised 283 patients, and 313 patients in the control group were eligible for analysis. No dif-- ferences were found with respect to the baseline demographic and indication for CD. The number of postpartum urinary bladder catheterizations due to urine retention was higher in the study group (5% vs. 1%, P-value = 0.003). No cases of 30- day readmission were recorded. Moreover, patients treated with neuraxial morphine required fewer repeat doses of postoperative anesthesia (oral analgesia 7.4 vs. 10.1, intravenous analgesia 0.29 vs. 0.31, oral opioids 0.06 vs. 3.70, intravenous opioids 0.01 vs. 0.45, P-value < 0.001 for all) Conclusions: While neuraxial morphine used during CD appears to be safe and effective, the risk of postoperative urinary retention seems to be increased due to its use. Cases of overt urinary retention treated by bladder catheterization does not lead to short-term complications.
- 1 December 2023
- Vol. 25 (12) , 799-803
When Do Women with Second Trimester Pregnancy Loss Need Repeated Doses of Misoprostol? Insights from a Teaching Hospital
Background: Cases of second trimester pregnancy loss can be treated either pharmacologically or by surgical evacuation. Misoprostol, an El-prostaglandin analog, is used to facilitate the evacuation of the uterus. Objectives: To determine the risk factors associated with patients who were treated with five or more repeated doses of misoprostol. Methods: We conducted a retrospective study of patients treated with vaginal misoprostol at our institution between December 2016 and October 2021 for second trimester pregnancyloss. Results: In total, 114 patients were eligible for analysis; 83 were treated with < 5 doses and 31 with > 5. We recorded each case in which repeated doses were administered, irrespective of predetermined conditions such as gravidity, parity, maternal age, or gestational age. Moreover, cases of five or more misoprostol dosing were not associated with an increased complications rate, except for the increased duration of hospitalization (3.1 vs. 2.2 days, P-value < 0.01). Conclusions: Repeated dosing could not be predicted before treatment among those treated with vaginally administered misoprostol for second trimester pregnancy loss. However, low complication rates of repeated dosing may reassure both physicians and patients regarding safety, efficacy, and future fertility.
- 1 December 2023
- Vol. 25 (12) , 799-803
When Do Women with Second Trimester Pregnancy Loss Need Repeated Doses of Misoprostol? Insights from a Teaching Hospital
Background: Cases of second trimester pregnancy loss can be treated either pharmacologically or by surgical evacuation. Misoprostol, an El-prostaglandin analog, is used to facilitate the evacuation of the uterus. Objectives: To determine the risk factors associated with patients who were treated with five or more repeated doses of misoprostol. Methods: We conducted a retrospective study of patients treated with vaginal misoprostol at our institution between December 2016 and October 2021 for second trimester pregnancyloss. Results: In total, 114 patients were eligible for analysis; 83 were treated with < 5 doses and 31 with > 5. We recorded each case in which repeated doses were administered, irrespective of predetermined conditions such as gravidity, parity, maternal age, or gestational age. Moreover, cases of five or more misoprostol dosing were not associated with an increased complications rate, except for the increased duration of hospitalization (3.1 vs. 2.2 days, P-value < 0.01). Conclusions: Repeated dosing could not be predicted before treatment among those treated with vaginally administered misoprostol for second trimester pregnancy loss. However, low complication rates of repeated dosing may reassure both physicians and patients regarding safety, efficacy, and future fertility.
- 2 November 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (4) , 1127-1134
Pain and anxiety management with virtual reality for office hysteroscopy: systemic review and meta-analysis
Purpose Office hysteroscopy (OH) is a commonly performed procedure, although it might be associated with some degree of pain and anxiety. Our aim was to determine the effects of virtual reality on pain and anxiety levels felt by patients undergoing OH. Methods MEDLINE, Embase, Google Scholar, Cochrane Library, clinicaltrials.gov, ProQuest, Grey literature, and manual searching of references within studies found in the initial search were systematically searched using the terms ‘Virtual Reality’ and ‘Hysteroscopy’ without time or language limitations. The review considered all studies assessing the impact of virtual reality (VR) over OH outcomes, and prospective randomized trials were included in the meta-analysis. Retrospective and case − control studies were excluded from the meta-analysis. Results We identified 17 studies, of which four randomized controlled studies were included in the meta-analysis (327 participants, 168 in the VR group and 159 in the control group). On a 0–10 scale, pain sensation and maximal pain sensation during the operation were not statistically different between study and control groups (relative risk (RR) = −0.64, 95% C.I (−1.57)0.29) and (RR = −0.93, 95% C.I (−3.33) − 1.47), respectively. Anxiety measurement was statistically lower in the study group (RR = −1.73, 95% C.I (−2.79) − ( −0.67)). Conclusions The available data suggest that VR techniques do not decrease the pain sensation during OH however, they do contribute to a reduction in the anxiety levels experienced by patients. PROSPERO registration number CRD42023432819.
- 2 November 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (4) , 1127-1134
Pain and anxiety management with virtual reality for office hysteroscopy: systemic review and meta-analysis
Purpose Office hysteroscopy (OH) is a commonly performed procedure, although it might be associated with some degree of pain and anxiety. Our aim was to determine the effects of virtual reality on pain and anxiety levels felt by patients undergoing OH. Methods MEDLINE, Embase, Google Scholar, Cochrane Library, clinicaltrials.gov, ProQuest, Grey literature, and manual searching of references within studies found in the initial search were systematically searched using the terms ‘Virtual Reality’ and ‘Hysteroscopy’ without time or language limitations. The review considered all studies assessing the impact of virtual reality (VR) over OH outcomes, and prospective randomized trials were included in the meta-analysis. Retrospective and case − control studies were excluded from the meta-analysis. Results We identified 17 studies, of which four randomized controlled studies were included in the meta-analysis (327 participants, 168 in the VR group and 159 in the control group). On a 0–10 scale, pain sensation and maximal pain sensation during the operation were not statistically different between study and control groups (relative risk (RR) = −0.64, 95% C.I (−1.57)0.29) and (RR = −0.93, 95% C.I (−3.33) − 1.47), respectively. Anxiety measurement was statistically lower in the study group (RR = −1.73, 95% C.I (−2.79) − ( −0.67)). Conclusions The available data suggest that VR techniques do not decrease the pain sensation during OH however, they do contribute to a reduction in the anxiety levels experienced by patients. PROSPERO registration number CRD42023432819.
- 31 August 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 308 (6) , 1791-1796
Does vaginal cleansing with iodine decreases infection rate in office hysteroscopy?
Purpose To determine whether preoperative vaginal cleansing with iodine-based solution prior to hysteroscopy, reduces postoperative infection rate compared to no vaginal cleansing. Methods A retrospective study at a single tertiary, university affiliated hospital of all individuals who have had an office hysteroscopy. Study group consisted of patients who have had preoperative vaginal cleansing with iodine-based solution and were compared to those who have not. Any procedural related complaints at the 30 days following the hysteroscopy were recorded. Results A total of 505 were available for analysis, 183 in the study group and 322 in the control group. The most common indications for operation were infertility evaluation (33.9% vs. 28.6%) and retained products of conception (33.3% vs. 29.2%), and most common procedures were diagnostic only (49.7% vs. 42.5%) followed by adhesiolysis (12% vs. 14.3%). No statistical differences were noted with regards to postoperative infections, as only one case of pelvic inflammatory disease was noted, in the iodine cleansing group (0.19% for postoperative infection). Conclusion Our comparative study may suggest that the use of preoperative iodine solution prior to office hysteroscopy does not decrease the postoperative infection rate up to 30 days, thus can be avoided.
- 31 August 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 308 (6) , 1791-1796
Does vaginal cleansing with iodine decreases infection rate in office hysteroscopy?
Purpose To determine whether preoperative vaginal cleansing with iodine-based solution prior to hysteroscopy, reduces postoperative infection rate compared to no vaginal cleansing. Methods A retrospective study at a single tertiary, university affiliated hospital of all individuals who have had an office hysteroscopy. Study group consisted of patients who have had preoperative vaginal cleansing with iodine-based solution and were compared to those who have not. Any procedural related complaints at the 30 days following the hysteroscopy were recorded. Results A total of 505 were available for analysis, 183 in the study group and 322 in the control group. The most common indications for operation were infertility evaluation (33.9% vs. 28.6%) and retained products of conception (33.3% vs. 29.2%), and most common procedures were diagnostic only (49.7% vs. 42.5%) followed by adhesiolysis (12% vs. 14.3%). No statistical differences were noted with regards to postoperative infections, as only one case of pelvic inflammatory disease was noted, in the iodine cleansing group (0.19% for postoperative infection). Conclusion Our comparative study may suggest that the use of preoperative iodine solution prior to office hysteroscopy does not decrease the postoperative infection rate up to 30 days, thus can be avoided.
- Open Access
- 13 July 2023
- Published by Springer Nature in Research Square
Does Vaginal Cleansing with Iodine Decreases Infection Rate in Office Hysteroscopy?
Purpose: To determine whether preoperative vaginal cleansing with iodine-based solution prior to hysteroscopy, reduces postoperative infection rate compared to no vaginal cleansing. Methods: A retrospective study at a single tertiary, university affiliated hospital of all individuals who have had an office hysteroscopy. Study group consisted of patients who have had preoperative vaginal cleansing with iodine-based solution and were compared to those who have not. Any procedural related complaints at the 30 days following the hysteroscopy were recorded. Results: A total of 505 were available for analysis, 183 in the study group and 322 in the control group. The most common indications for operation were infertility evaluation (33.9% vs. 28.6%) and retained products of conception (33.3% vs. 29.2%), and most common procedures were diagnostic only (49.7% vs. 42.5%) followed by adhesiolysis (12% vs. 14.3%) No statistical differences were noted with regards to postoperative infections, as only one case of pelvic inflammatory disease was noted, in the iodine cleansing group (0.19% for postoperative infection). Conclusion: Our comparative study may suggest that the use of preoperative iodine solution prior to office hysteroscopy does not decrease the postoperative infection rate up to 30 days, thus can be avoided.
- 13 July 2023
- Published by Springer Nature in Research Square
Open AccessDoes Vaginal Cleansing with Iodine Decreases Infection Rate in Office Hysteroscopy?
Purpose: To determine whether preoperative vaginal cleansing with iodine-based solution prior to hysteroscopy, reduces postoperative infection rate compared to no vaginal cleansing. Methods: A retrospective study at a single tertiary, university affiliated hospital of all individuals who have had an office hysteroscopy. Study group consisted of patients who have had preoperative vaginal cleansing with iodine-based solution and were compared to those who have not. Any procedural related complaints at the 30 days following the hysteroscopy were recorded. Results: A total of 505 were available for analysis, 183 in the study group and 322 in the control group. The most common indications for operation were infertility evaluation (33.9% vs. 28.6%) and retained products of conception (33.3% vs. 29.2%), and most common procedures were diagnostic only (49.7% vs. 42.5%) followed by adhesiolysis (12% vs. 14.3%) No statistical differences were noted with regards to postoperative infections, as only one case of pelvic inflammatory disease was noted, in the iodine cleansing group (0.19% for postoperative infection). Conclusion: Our comparative study may suggest that the use of preoperative iodine solution prior to office hysteroscopy does not decrease the postoperative infection rate up to 30 days, thus can be avoided.